United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

17 Jan 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Thu, Jan 12 2017

BRIEF-Grifols buys 49 pct in US-based Access Biologicals for $51 million

* Invests in US-based Access Biologicals via acquisition of 49 percent of its voting rights for $51 million

BRIEF-Grifols starts refinancing of part of its bank debt

* Starts refinancing process of part of its bank debt for a total amount of $6.3 billion

Grifols to buy Hologic's stake in blood screening JV for $1.85 billion

Spain's Grifols SA , which develops plasma protein therapies, said it would buy U.S. medical device maker Hologic Inc's interest in their blood screening joint venture for $1.85 billion in cash.

BRIEF-Grifols 9-month net profit rises to 406.1 mln euros

* 9-month net profit 406.1 million euros ($448.5 million)versus 401.6 million euros year ago

BRIEF-Oncbiomune signs term sheet to acquire Vitel Laboratorios, S.A. De C.V.

* Oncbiomune signs term sheet to acquire Vitel Laboratorios, s.a. De c.v. Source text for Eikon: Further company coverage:

BRIEF-Grifols to pay FY 2016 interim dividend of 0.18 euro/shr

* Says to pay interim dividend for 2016 of 0.18 euro ($0.1972) per share on Dec. 7 Source text for Eikon: Further company coverage: ($1 = 0.9127 euros) (Gdynia Newsroom)

BRIEF-Medica Sur receives green light to buy LMP

* Said on Wednesday received an approval from a competition watchdog to acquire Laboratorio Medico Polanco (LMP) and its units Laboratorios Clinicos de Puebla (LCP), Laboratorios Clinicosde Puebla en Bioequivalencia (LCPB) and other units

BRIEF-Prim buys branches from Laboratorios Milo for fixed price of 1.2 mln euros

* Buys pharmacy, orthopedics and podiatry branches from Laboratorios Milo for 1.24 million euros ($1.39 million) and variable price depending on results of the branches in 2016-2020 Source text for Eikon:

BRIEF-Grifols' phase I Alzheimer vaccine study shows good safety profile, tolerability

* Says unit Araclon Biotech presents phase I Alzheimer vaccine results showing good safety profile and tolerability

BRIEF-Grifols reports H1 EBITDA at 553.6 mln euros

* H1 net profit 264.4 million euros ($293.1 million) versus 256 million euros in Reuters poll

Select another date: